Compare Stocks → “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALRNNASDAQ:GEMPNASDAQ:KTOVNASDAQ:KZIANASDAQ:MTFB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$5.00+1.4%$5.40$1.01▼$7.42$84.85M2.2263,976 shs17,122 shsGEMPGemphire Therapeutics$3.10+2.6%$4.97$0.24▼$1.49$46.10M2.82127,174 shs39,360 shsKTOVPurple Biotech$0.51+4.1%$4.16$2.20▼$14.40$8.06M2.371.18 million shs270,939 shsKZIAKazia Therapeutics$0.39+0.3%$0.30$0.19▼$1.41$6.37M2.12732,626 shs39,275 shsMTFBMOTIF BIO PLC/S$0.11$0.10$0.08▼$11.50N/AN/AN/A867,698 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics+3.79%+16.00%-14.56%+1.86%+230.89%GEMPGemphire Therapeutics-0.64%-8.82%-30.49%+0.98%+350.12%KTOVPurple Biotech+4.63%+18.05%-23.60%-15.95%-74.11%KZIAKazia Therapeutics-1.52%+13.38%+45.15%+5.28%-70.66%MTFBMOTIF BIO PLC/S0.00%0.00%0.00%0.00%0.00%See this before next week's Fed meeting (Ad)See this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) Click here to see it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron Therapeutics1.2693 of 5 stars3.53.00.00.00.61.70.0GEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics3.00Buy$19.00280.00% UpsideGEMPGemphire TherapeuticsN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/ACurrent Analyst RatingsLatest ALRN, KTOV, MTFB, KZIA, and GEMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AGEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AKTOVPurple Biotech$1M8.06N/AN/A$5.56 per share0.09KZIAKazia Therapeutics$20K318.65N/AN/A$0.50 per share0.78MTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)GEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AKTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/AKZIAKazia Therapeutics-$13.78MN/A0.00N/AN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A4.174.17GEMPGemphire TherapeuticsN/A0.670.67KTOVPurple BiotechN/A2.22N/AKZIAKazia TherapeuticsN/A0.71N/AMTFBMOTIF BIO PLC/SN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%GEMPGemphire Therapeutics17.53%KTOVPurple Biotech30.72%KZIAKazia Therapeutics30.89%MTFBMOTIF BIO PLC/SN/AInsider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.57%GEMPGemphire Therapeutics22.70%KTOVPurple Biotech2.98%KZIAKazia Therapeutics1.00%MTFBMOTIF BIO PLC/SN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableKTOVPurple Biotech915.73 millionN/ANot OptionableKZIAKazia Therapeutics2,02116.34 million16.18 millionOptionableMTFBMOTIF BIO PLC/S7N/AN/ANot OptionableALRN, KTOV, MTFB, KZIA, and GEMP HeadlinesSourceHeadlineRice Biotech Launch Pad startup Motif Neurotech announces peer-reviewed publication on wireless cortical stimulator for precise neuromodulationtmcnet.com - April 12 at 4:46 PMRBM17 (F-5) AClabroots.com - February 24 at 6:32 PMSmall-molecule A485 mobilizes white blood cells on demandmsn.com - February 3 at 9:42 PMROBIT PLC’S FINANCIAL INFORMATION AND ANNUAL GENERAL MEETING IN 2024finance.yahoo.com - November 3 at 11:21 PM4GLOBAL plc's (LON:4GBL) Stock Is Going Strong: Have Financials A Role To Play?finance.yahoo.com - August 9 at 4:20 PMIs There An Opportunity With Stelrad Group PLC's (LON:SRAD) 44% Undervaluation?finance.yahoo.com - August 2 at 10:41 AMDAVA - Endava plcfinance.yahoo.com - June 13 at 9:03 PMLacklustre Performance Is Driving NIOX Group Plc's (LON:NIOX) Low P/Sfinance.yahoo.com - May 25 at 5:59 PMInovyn launches world’s first bio-attributed PVCplasticstoday.com - May 10 at 10:07 AMCushman & Wakefield PLC CWK Stock Quotemorningstar.com - April 27 at 6:51 PMThe Dizzying ‘Mrs. Davis’ Refuses to Settle for Simple Weirdnessthedailybeast.com - April 23 at 6:35 PMIneos Styrolution Launches World’s First Fully Bio-Attributed ABSplasticstoday.com - March 16 at 7:23 PMEvli Plc: Financial Statements Bulletin January-December 2022finance.yahoo.com - February 22 at 9:37 AMEnzyme-Linked Immunosorbent Assay (ELISA) Testing Market Size, Analysis with Key Players having Regional Statistics and Application Forecast to 2029marketwatch.com - February 13 at 7:05 AMLuciferase Assay Kits Market Trends and Opportunities and Forecast to 2028 with Top Countries Datamarketwatch.com - February 13 at 7:05 AMAccenture PLC Cl Awsj.com - February 10 at 9:17 PMConsti Plc's financial reporting and Annual General Meeting in 2023finance.yahoo.com - November 16 at 10:44 PMInternational Space Station’s BFF 3D Prints Human Tissueplasticstoday.com - November 4 at 2:28 PMImmunoprotein Reagents and Assay Kits Market Research on Present State and Future Growth Prospects of Key Players, Forecast by 2022 To 2028marketwatch.com - October 20 at 9:47 AMThe race to native code execution in PLCs: using RCE to uncover Siemens SIMATIC S7-1200/1500 hardcoded cryptographic keysitwire.com - October 14 at 3:22 PMAt $3m, Bluebird Bio’s new gene therapy is the most expensive drug in the USbostonglobe.com - October 13 at 11:02 PMMotif Biofool.co.uk - October 3 at 1:53 PMAntibodies once acted only as protein blockers. Now, scientists are finding new ways to make them protein destroyersendpts.com - September 23 at 9:43 AMBio-Inspired Composite Materials Are Both Stretchy and Tear-Resistantdesignnews.com - August 22 at 11:49 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Gemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Purple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.Kazia TherapeuticsNASDAQ:KZIAKazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.MOTIF BIO PLC/SNASDAQ:MTFBMotif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.